Eventual response to alemtuzumab therapy according to the level of peripheral blood response at weeks 2 and 4
. | No. patients (%), by level of peripheral blood response, × 109/L . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Absolute B-cell count . | > 0.1 . | > 0.01 . | > 0.001 . | > 0.0001 . | |||
| Wk 2 of therapy | |||||||
| NR | 12 (44) | 19 (70) | 25 (93) | 27 (100) | |||
| PR/CR | 4 (29) | 7 (50) | 7 (50) | 13 (93) | |||
| Wk 4 of therapy | |||||||
| NR | 5 (19) | 12 (44) | 23 (85) | 27 (100) | |||
| PR/CR | 0 (0) | 2 (14) | 6 (43) | 10 (71) | |||
. | No. patients (%), by level of peripheral blood response, × 109/L . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Absolute B-cell count . | > 0.1 . | > 0.01 . | > 0.001 . | > 0.0001 . | |||
| Wk 2 of therapy | |||||||
| NR | 12 (44) | 19 (70) | 25 (93) | 27 (100) | |||
| PR/CR | 4 (29) | 7 (50) | 7 (50) | 13 (93) | |||
| Wk 4 of therapy | |||||||
| NR | 5 (19) | 12 (44) | 23 (85) | 27 (100) | |||
| PR/CR | 0 (0) | 2 (14) | 6 (43) | 10 (71) | |||
It is not possible to discriminate between responders (n = 14) and nonresponders (n = 27) according to week 2 or week 4 B-cell counts alone.